1. South Korea Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
INVITES BIOCORE CO. LTD

INVITES BIOCORE CO. LTD

KKRX:216400
1,369.00
KRW
+9.00
(+0.66%)
-1,014.74EPS
34.88BMarket Cap
INVITES BIOCORE CO. LTD
KRX:216400
(Korea Stock Exchange)

Recent

price

1,369.00

P/E

ratio

- -

div

yld

1.91%

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
KRW
3,431.56
3,602.9
3,534.3
3,144.47
3,047.08
3,251.82
2,655.78
3,309.98
2,913.18
1,686.81
2,173.36
Revenue per Share
-43
377
18
-505
162
273
93
-322
-910
-1,043
-808.56
Basic EPS, GAAP
-1,319.5
-98.12
152.33
97.86
723.98
-302.75
749.07
-211.72
-441.31
691.16
473.98
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
26.12
Dividend per Share
2,085.79
2,447.86
2,499.9
1,988.63
2,120.55
3,203.65
3,303.7
4,292.12
3,252.32
1,810.23
346.65
Book Value per Share
1,219.53
1,512.56
1,723.67
1,891.98
2,039.09
3,152.68
3,166.37
2,115.35
2,738.17
1,418.57
144.34
Tangible Book Value per Share
6
7
7
7
7
7
8
8
8
8
8
Basic Weighted Avg Shares
20,134
24,390
24,646
21,491
20,908
23,592
20,234
25,357
22,319
12,907
16,644
Sales/Revenue/Turnover
5.54
7.49
5.72
1.37
6.42
9.04
11.21
11.13
-23.96
-4.29
1.31
Operating Margin (%)
1,004
1,292
1,720
1,583
1,907
2,027
1,917
2,613
3,622
3,505
2,868
Depreciation Expense
-252
2,552
126
-3,451
1,112
1,981
709
-2,467
-6,972
-7,981
-6,192
Net Income, GAAP
36.36
12.22
7.05
- -
21.11
14.96
0.02
- -
- -
- -
- -
Effective Tax Rate (%)
-1.25
10.46
0.51
-16.06
5.32
8.4
3.5
-9.73
-31.24
-61.83
-37.2
Profit Margin (%)
5,387
8,061
9,183
10,628
12,902
21,610
48,453
19,980
-19,662
-36,476
-63,654
Working Capital
1,036
700
- -
- -
225
252
17,808
597
512
1,756
2,108
LT Debt
14,118
16,568
17,062
13,599
14,531
24,534
25,300
33,941
39,920
13,863
2,655
Total Equity
- -
9.31
7.34
- -
7.26
8.86
6.52
- -
- -
- -
- -
Return on Invested Capital (%)
- -
15.2
0.91
- -
8.02
10.14
10.4
- -
- -
- -
- -
Return on Capital (%)
- -
16.63
0.75
-22.51
7.9
10.14
2.84
-8.48
-24.13
-41.17
-74.97
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

KRW

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1.55%
-18.25%
-80.85%
Free Cash Flow
-55.74%
-133.52%
-31.37%
Net Income, GAAP
-444.8%
-67.54%
-22.41%
Sales/Revenue/Turnover
0.54%
-2.82%
28.95%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
22,319
2024
- -
- -
- -
- -
12,907
2025
- -
- -
- -
- -
16,644

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-910
2024
- -
- -
- -
- -
-1,043
2025
- -
- -
- -
- -
-808.56

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
26.12
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Fiserv, Inc. (NASDAQ:FISV)
Business
Invites Biocore Co., Ltd. is a South Korea-based biotechnology and clinical contract research organization (CRO) that specializes in bioanalytical services, clinical trial management, genomic analysis, and molecular in vitro diagnostics. Founded in 2001 and headquartered in Seoul, South Korea, the company operates primarily through two core business segments: the Clinical CRO & Bioanalysis Division and the Genomics & In Vitro Diagnostics (IVD) Division. Through its Clinical CRO & Bioanalysis segment, the company provides comprehensive clinical development solutions including early-phase clinical study design; bioequivalence (BE) testing; Phase I through Phase IV clinical trial management; regulatory affairs consulting; clinical data management; biostatistical analysis; and high-throughput bioanalysis utilizing liquid chromatography-tandem mass spectrometry (LC-MS/MS) for pharmacokinetic (PK), pharmacodynamic (PD), and toxicokinetic (TK) evaluation of small molecules, biologics, peptide therapeutics, and advanced therapeutic modalities. Through its Genomics & IVD segment, the company develops, manufactures, and markets molecular diagnostic kits and genomic testing services, including real-time polymerase chain reaction (RT-PCR) kits for human papillomavirus (HPV) genotyping, respiratory pathogens, and sexually transmitted infections; next-generation sequencing (NGS) and microarray-based genetic profiling; non-invasive prenatal testing (NIPT); cancer genomic panels; hereditary disease screening; and pharmacogenomic testing. The company serves pharmaceutical manufacturers, biotechnology companies, clinical laboratories, hospitals, and academic research institutions across South Korea and international markets. In recent developments, the company rebranded from Biocore Co., Ltd. to Invites Biocore Co., Ltd. to reflect its strategic integration into the Invites Ecosystem consortium alongside affiliates including Invites Healthcare and Invites Genomics. Under this strategic reorganization, Invites Biocore has expanded its bioanalytical portfolio to support emerging drug modalities such as antibody-drug conjugates (ADCs) and cell and gene therapies, while entering strategic collaborations with academic medical institutions and digital health partners to establish integrated multi-omics genomic data platforms and advance personalized precision medicine capabilities.